CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 211 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a weekAI-extracted
Key inclusion· 1
  • ✓Diagnosis of plaque psoriasis
Key exclusion· 1
  • ✕Cannot receive certain psoriasis medications during the study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00078819
NCT00078819Phase 3Completed
CompareCT.gov

Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS)

Amgen·interventional·Posted Mar 9, 2004·Updated Jul 29, 2019

In Brief

A Phase 3 clinical trial evaluating Etanercept and Placebo for Psoriasis. Completed, enrolled 211 participants.

Detailed Summary

This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2004
Enrollment StartSep 8, 2004
Primary CompletionFeb 1, 2006
Study CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 22.3 years ago

Interventions

Etanerceptdrug

Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week

Placebodrug

Placebo matching to etanercept administered by subcutaneous injection once a week